Kiniksa Pharmaceuticals Ltd Class A (NASDAQ:KNSA) - Share price


Stock Report

Kiniksa Pharmaceuticals Ltd KNSA

Last Price
$12.16

Day Change
-0.76|-5.88%

As of 11/08/2022
18:18:43 EDT | USD
Minimum 15 Minutes Delay.

Last Close12.92
Day Range11.87 - 12.98
Mkt Cap844.80Mil
52-Wk Range7.36 - 15.25
Yield %-
ISINBMG5269C1010
Volume351,105
P/E4.94
P/S9.33
P/CF-9.12

Share Price

Financials
201920202021
More ...
Income Statement
Revenue0.000.0038.54
Operating Income-169.96-157.36-156.64
Net Income-161.87-161.38-157.92
Basic EPS-2.99-2.61-2.30
Avg. Diluted Shares Outstanding546269
Balance Sheet
Current Assets241.63333.25196.45
Non Current Assets12.9116.2236.35
Total Assets254.53349.46232.80
Current Liabilities27.8331.8544.82
Total Liabilities---
Total Equity225.42311.94185.04
Cash Flow
Operating Cash Flow-158.37-136.53-126.30
Capital Expenditure-3.20-0.28-20.42
Free Cash Flow-161.57-136.82-146.71

In millions, except "Basic EPS". Currency is USD.

Company Profile

Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its clinical-stage product candidates include Rilonacept, for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; Vixarelimab; and KPL-404.

Sector

Healthcare

Industry

Biotechnology

Stock Style

Small-Value

Fiscal Year Ends

December

Employees

215
Key Stats
More ...
Price/Earning TTM-7.98
Price/Book5.85
Price/Sales TTM12.57
Rev Growth (3 year avg)-
EPS Growth (3 year avg)-
Operating Margin % TTM-406.38
Net Margin % TTM-409.72
ROE TTM-63.55
Debt/Equity0.01
Dividends
PreviousLatest
More ...
Declared Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2022 Morningstar. All rights reserved.